ResMed Stock Slides 9.2% Over 9 Straight Down Days
A nine-day slide in this health care stock has drawn attention to the gap between its price and its performance.
ResMed (RMD) stock has now moved lower for 9 consecutive trading days, resulting in a cumulative loss of 9.2%. That streak has erased about $3.2 billion from the company’s market value, which now stands at about $32 billion.
For an investor holding the stock, the move is a significant drawdown. The stock trades at about $218.27 a share as of 9/11/2026, closer to its 52-week low of $182.3 than its high of $280.31.
The streak next to the S&P 500
Here is how RMD stock stacks up against the S&P 500 over the streak and the periods around it:
| Return Period | RMD | S&P 500 |
|---|---|---|
| 1D | -0.6% | 0.9% |
| 9D (Current Streak) | -9.2% | -0.7% |
| 1M (21D) | -3.1% | -1.2% |
| 3M (63D) | 13.8% | 3.6% |
| YTD 2026 | -8.6% | 11.9% |
| 2025 | 6.3% | 16.4% |
| 2024 | 34.2% | 23.3% |
| 2023 | -16.5% | 24.2% |
The stock’s slide contrasts with its business metrics.
Available sources do not indicate a specific driver behind the multi-day selling, though the company’s trailing operating results remain intact. ResMed’s revenue over the last twelve months grew 9.9%, ahead of the S&P 500 median of 8.3%. Its operating margin is 33.8%, compared to an 18.6% median for the index. The company’s 3-year average annual revenue growth is 10.2%, and its free cash flow yield is 5.2%.
Despite this, the stock now trades at a price-to-earnings multiple of 20.7, below the S&P 500 Health Care median of 25.1. The move is also specific to the company; over the same 9 trading days the S&P 500 returned -0.7%. While notable, such streaks are not unique: 2 other S&P 500 stocks are currently on losing streaks of 9 days or more.
Interpreting the streak
A long streak is information. It tells you that a stock has sustained momentum and captured the market’s attention, but it does not provide an instruction to buy or sell. The disciplined move is to treat the streak as a trigger to check the business against its new price.
The fundamental picture here shows a profitable, growing business trading at a below-median multiple for its sector. That is the starting point for assessing whether the market’s recent verdict is one to follow or to fade.
A slide like this poses an obvious follow-up: which marked-down stocks are actually worth buying? Our Buy the Dip screen runs that test every day, flagging beaten-down names whose fundamentals still hold up.
Those watching the group rather than this one name have another route: our ETF Scorecard shows how the healthcare funds stack up. Any one of those funds is still a concentrated bet on that one theme, though, which is exactly the gap the portfolio below closes.
Falling prices test conviction. Rules do not flinch
A losing streak forces a choice on every holder: sell into weakness, average down, or freeze. All three are emotional answers to what should be an analytical question, and decisions made that way tend to be expensive ones.
The Trefis High Quality (HQ) Portfolio takes the emotion out: about 30 quality businesses screened for the fundamentals that survive bad stretches, held and rebalanced by rules. It has a track record of outpacing a benchmark that combines the three major indices – the S&P 500, S&P Mid-cap, and Russell 2000. Let the rules decide, not the tape.